COMPANY RESEARCHBeOne Medicines Ltd.
BeOne Medicines develops and commercializes cancer treatments, combining internal discovery with clinical development and global commercialization. The company works across hematologic malignancies and solid tumors and uses a portfolio of therapeutic approaches rather than a single modality. Its official annual report identifies the same issuer across Nasdaq, Hong Kong and Shanghai listings; these securities must be stored under one company identity, not as separate companies. Its therapeutic development spans targeted oncology medicines and biologic treatment approaches.
Company at a glance
Corporate information
- Company entity
- BeOne Medicines Ltd.（formerly BeiGene）
- Headquarters / principal office
- Cambridge, MassachusettsSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.
Sources (1)
- Company-managed LinkedIn profile — self-reported locationChecked 2026-11-04; source publication date retained where stated
- Founded
- 2010
Sources (1)
- Our History of Innovation in Cancer CareNot stated
- Ownership / capital status
- Publicly tradedPublicly traded
Sources (1)
- BeOne Medicines 公司主页Not stated
- Official corporate reference
- https://beonemedicines.com/
Sources (1)
- Our History of Innovation in Cancer CareNot stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Official corporate website audit2026-11-04 retrieval; original page date where stated
- Latest financing / award identified
- 2011 · Early external equity investment (historical) · $20 million
Sources (1)
- Our History of Innovation in Cancer CareNot stated
Company history states that Merck KGaA provided an early investment in 2011; this is not the latest financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
BeOne Medicines develops and commercializes cancer treatments, combining internal discovery with clinical development and global commercialization. The company works across hematologic malignancies and solid tumors and uses a portfolio of therapeutic approaches rather than a single modality. Its official annual report identifies the same issuer across Nasdaq, Hong Kong and Shanghai listings; these securities must be stored under one company identity, not as separate companies. Its therapeutic development spans targeted oncology medicines and biologic treatment approaches.
Nasdaq: ONC HKEX: 06160 SSE STAR: 688235
oncology · small-molecule · biologics
oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The website lists CaDAnCe-302 for tacabrutideg/BGB-16673 as Phase 3. CDAC is the company's term for chimeric degradation-activating compounds.
Business, technology & evidence
- 2026 conference materials include Phase 1 updates in previously treated CLL and other B-cell malignancies.
- Current legal identity and leadershipformer BeiGene, Ltd. officially became BeOne Medicines Ltd. and redomiciled from the Cayman Islands to Switzerland effective May 27, 2025. The announcement lists NASDAQ: ONC, HKEX: 06160 and SSE: 688235, and identifies John V. Oyler as co-founder, Chair and CEO.
- CDAC pipeline, page updated October 2026the pipeline describes tacabrutideg as an oral BTK CDAC and shows multiple Phase 3 CLL/SLL studies. It lists BGB-45035, an IRAK4 CDAC, in Phase 1 immunology/inflammation development. The page states that safety and efficacy are not established for investigational products or uses.
- BeOne Medicines develops and commercializes cancer treatments, combining internal discovery with clinical development and global commercialization. The company works across hematologic malignancies and solid tumors and uses a portfolio of therapeutic approaches rather than a single modality. Its official annual report identifies the same issuer across Nasdaq, Hong Kong and Shanghai listings; these securities must be stored under one company identity, not as separate companies. Its therapeutic development spans targeted oncology medicines and biologic treatment approaches.
- SecuritiesNasdaq: ONC / HKEX: 06160 / SSE STAR: 688235
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| tacabrutideg / BGB-16673 | BTK · B-cell malignancies including CLL / SLL | Phase 3 | Human results reported by the source; see facts and original materials for type and quality |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Stages must be separated by indication. Phase 3 initiation does not establish endpoint achievement or approval. Peer-company trade secret litigation is ongoing; no outcome is presumed.
- Oncology Pipeline / CaDAnCe-302 ↗BeOne · Undated · 2026-10-31accessed
- ASCO and EHA 2026 abstracts ↗BeOne · 2026-05
- Phase 1 CaDAnCe-101 BGB-16673 in R/R CLL/SLL ↗BeOne Medical Affairs / EHA 2026 · 2026-06
- BeOne Medicines Launches Following Redomiciliation to Switzerland ↗BeOne Medicines · 2025-05-27
- Official issuer and R&D disclosure · BeOne Medicines Ltd. ↗BeOne Medicines Ltd. ·
- Official issuer and R&D disclosure · BeOne Medicines Ltd. ↗BeOne Medicines Ltd. ·
- Official issuer and R&D disclosure · BeOne Medicines Ltd. ↗BeOne Medicines Ltd. ·
- Official issuer and R&D disclosure · BeOne Medicines Ltd. ↗BeOne Medicines Ltd. ·
- Our History of Innovation in Cancer Care ↗BeOne Medicines · Not stated
- BeOne Medicines 公司主页 ↗BeOne／LinkedIn · Not stated
- Official corporate website audit ↗BeOne Medicines (formerly BeiGene) · 2026-11-04 retrieval; original page date where stated
- Company-managed LinkedIn profile — self-reported location ↗BeOne Medicines (formerly BeiGene) · Checked 2026-11-04; source publication date retained where stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.